SLC29A1 and juvenile Huntington disease: This implies that dysfunction in its levels might lead to some neurological impairments; concurrently, reduced adenosine levels have been observed in disorders such as Alzheimer’s and Huntington’s diseases and enhancing adenosine tone through ENT1 blockade rescued some pathological hallmarks in in vivo models of these diseases [15,16].